Patients with type 2 diabetes (T2D) suffer from a higher risk of cardiovascular events and renal events, which are strongly associated with morality [1–3]. The novel anti-hyperglycemic agent, glucagon-like peptide 1 receptor agonist (GLP-1RA) has drawn a great deal of attention due to its potent efficacies in lowering glycemia, losing body weight, reducing blood pressure and more importantly contributing to favorable cardiorenal prognosis. Published cardiovascular outcome trials (CVOTs) have validated the substantial cardiovascular benefits of GLP-1RAs [4–8].
